vs

Side-by-side financial comparison of OHIO VALLEY BANC CORP (OVBC) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

OHIO VALLEY BANC CORP is the larger business by last-quarter revenue ($16.2M vs $13.7M, roughly 1.2× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 24.4%, a 51.3% gap on every dollar of revenue. OHIO VALLEY BANC CORP produced more free cash flow last quarter ($17.0M vs $-2.1M).

Valley National Bank of Arizona was a bank based in Phoenix, Arizona, founded in 1900 and acquired by Bank One in 1992. The bank was one of Arizona's leading financial institutions during the 20th century and the last major independent bank in Arizona at the time of its acquisition.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

OVBC vs XLO — Head-to-Head

Bigger by revenue
OVBC
OVBC
1.2× larger
OVBC
$16.2M
$13.7M
XLO
Higher net margin
XLO
XLO
51.3% more per $
XLO
75.7%
24.4%
OVBC
More free cash flow
OVBC
OVBC
$19.1M more FCF
OVBC
$17.0M
$-2.1M
XLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OVBC
OVBC
XLO
XLO
Revenue
$16.2M
$13.7M
Net Profit
$4.0M
$10.4M
Gross Margin
Operating Margin
30.7%
-86.5%
Net Margin
24.4%
75.7%
Revenue YoY
-4.6%
Net Profit YoY
57.3%
179.1%
EPS (diluted)
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OVBC
OVBC
XLO
XLO
Q4 25
$16.2M
$13.7M
Q3 25
$16.3M
$19.1M
Q2 25
$17.4M
$8.1M
Q1 25
$16.8M
$2.9M
Q4 24
$17.0M
Q3 24
$15.4M
Q2 24
$14.7M
Q1 24
$14.9M
Net Profit
OVBC
OVBC
XLO
XLO
Q4 25
$4.0M
$10.4M
Q3 25
$3.0M
$-16.3M
Q2 25
$4.2M
$-15.8M
Q1 25
$4.4M
$-13.3M
Q4 24
$2.5M
Q3 24
$2.7M
Q2 24
$3.0M
Q1 24
$2.8M
Operating Margin
OVBC
OVBC
XLO
XLO
Q4 25
30.7%
-86.5%
Q3 25
22.9%
-10.1%
Q2 25
29.8%
-177.7%
Q1 25
33.1%
-472.7%
Q4 24
18.1%
Q3 24
21.3%
Q2 24
24.7%
Q1 24
22.8%
Net Margin
OVBC
OVBC
XLO
XLO
Q4 25
24.4%
75.7%
Q3 25
18.5%
-85.4%
Q2 25
24.2%
-196.0%
Q1 25
26.2%
-452.7%
Q4 24
14.8%
Q3 24
17.6%
Q2 24
20.3%
Q1 24
18.8%
EPS (diluted)
OVBC
OVBC
XLO
XLO
Q4 25
$-3.74
Q3 25
$-0.11
Q2 25
$-0.16
Q1 25
$-0.18
Q4 24
Q3 24
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OVBC
OVBC
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$45.9M
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$170.3M
$35.3M
Total Assets
$1.6B
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OVBC
OVBC
XLO
XLO
Q4 25
$45.9M
$137.5M
Q3 25
$89.3M
$103.8M
Q2 25
$54.6M
$121.6M
Q1 25
$120.6M
$89.1M
Q4 24
$83.1M
Q3 24
$82.2M
Q2 24
$107.7M
Q1 24
$129.1M
Stockholders' Equity
OVBC
OVBC
XLO
XLO
Q4 25
$170.3M
$35.3M
Q3 25
$164.4M
$-8.1M
Q2 25
$160.8M
$7.1M
Q1 25
$155.7M
$10.7M
Q4 24
$150.3M
Q3 24
$152.2M
Q2 24
$145.8M
Q1 24
$145.8M
Total Assets
OVBC
OVBC
XLO
XLO
Q4 25
$1.6B
$154.7M
Q3 25
$1.6B
$133.7M
Q2 25
$1.5B
$133.8M
Q1 25
$1.5B
$103.7M
Q4 24
$1.5B
Q3 24
$1.5B
Q2 24
$1.4B
Q1 24
$1.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OVBC
OVBC
XLO
XLO
Operating Cash FlowLast quarter
$18.1M
$-2.0M
Free Cash FlowOCF − Capex
$17.0M
$-2.1M
FCF MarginFCF / Revenue
105.2%
-15.3%
Capex IntensityCapex / Revenue
6.4%
0.7%
Cash ConversionOCF / Net Profit
4.57×
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$26.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OVBC
OVBC
XLO
XLO
Q4 25
$18.1M
$-2.0M
Q3 25
$5.3M
$-17.5M
Q2 25
$4.5M
$-14.5M
Q1 25
$496.0K
$29.0M
Q4 24
$13.1M
Q3 24
$5.6M
Q2 24
$4.2M
Q1 24
$928.0K
Free Cash Flow
OVBC
OVBC
XLO
XLO
Q4 25
$17.0M
$-2.1M
Q3 25
$5.0M
Q2 25
$4.4M
$-14.9M
Q1 25
$138.0K
$29.0M
Q4 24
$11.7M
Q3 24
$5.4M
Q2 24
$3.9M
Q1 24
$234.0K
FCF Margin
OVBC
OVBC
XLO
XLO
Q4 25
105.2%
-15.3%
Q3 25
30.4%
Q2 25
25.1%
-184.0%
Q1 25
0.8%
988.3%
Q4 24
68.7%
Q3 24
35.1%
Q2 24
26.3%
Q1 24
1.6%
Capex Intensity
OVBC
OVBC
XLO
XLO
Q4 25
6.4%
0.7%
Q3 25
2.1%
0.0%
Q2 25
0.6%
5.0%
Q1 25
2.1%
0.8%
Q4 24
8.4%
Q3 24
1.2%
Q2 24
2.2%
Q1 24
4.7%
Cash Conversion
OVBC
OVBC
XLO
XLO
Q4 25
4.57×
-0.19×
Q3 25
1.75×
Q2 25
1.06×
Q1 25
0.11×
Q4 24
5.21×
Q3 24
2.06×
Q2 24
1.41×
Q1 24
0.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons